Bevacizumab Cheaper Than Ranibizumab for Macular DegenerationBevacizumab Cheaper Than Ranibizumab for Macular Degeneration
Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration. Medscape Medical News
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Ophthalmology News Source Type: news
More News: Age-Related Macular Degeneration (AMD) | Avastin | Health | Lucentis | Opthalmology | Ranibizumab Injection